In HR+/HER- early breast cancer, the DFS benefits of adjuvant ribociclib plus NSAI treatment compared to NSAI alone persisted even a year after treatment completion.

Itovebi, Ibrance, and Faslodex significantly improved OS in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer compared to placebo. The INAVO120 trial showed a median OS of 34.0 months ...

Patients receiving ribociclib 400 mg had a shorter QTcF (12.5 vs 19.7 ms at cycle 1 day 15, 2 hours post-dose) and a lower ...

In breast cancer patients with a high recurrence score, the 5-year disease-free rate was significantly higher for patients receiving taxanes with anthracycline and cyclophosphamide than for those ...

The evERA study showed significant PFS improvements with giredestrant plus everolimus in ER-positive, HER2-negative breast ...

In September 2025, the U.S. Food and Drug Administration (FDA) approved several new cancer therapies and supportive care ...

The study did meet the primary PFS primary end point; the median PFS for dato-DXd is 6.9 months vs 4.9 months in the ...

HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy The ...

Already a blockbuster therapy for advanced breast cancer and other indications like gastric cancer, Enhertu made revenues of ...